Case Studies

Featured

Ambrx Biopharma, Inc. (NASDAQ: AMAM): Investor Relations Program

BACKGROUND LifeSci embarked on a journey with Ambrx, beginning in November 2022, with a shared vision of enhancing its market presence and investor relations landscape. Over the course of this partnership, LifeSci's approach was multifaceted, aiming not just to amplify Ambrx's visibility, but to weave a narrative...

Read More
Crinetics Pharmaceuticals (NASDAQ: CRNX): Investor Relations Program

LIFESCI ACTIVITIES: Transparency and Communication: LifeSci helped Crinetics to determine appropriate expectations, craft messaging around those expectations, and carry through with them. Investor Education: LifeSci...

Read More
Ambrx Biopharma, Inc. (NASDAQ: AMAM): Investor Relations Program

BACKGROUND LifeSci embarked on a journey with Ambrx, beginning in November 2022, with a shared vision of enhancing its market presence and investor relations landscape....

Read More
Vyne Therapeutics (NASDAQ: VYNE): Investor Relations Program

BACKGROUND Vyne Therapeutics engaged LifeSci Advisors in a strategic partnership to elevate its presence among global investors since 2014. LIFESCI’S ACTIVITIES • Thorough market research,...

Read More
Verrica Pharmaceuticals (NASDAQ:VRCA): Investor Relations Program

BACKGROUND Verrica Pharmaceuticals has been a LifeSci client since December 2022. As part of the strategy to raise the Company’s visibility amongst global investors, LifeSci...

Read More
Abivax (ENXTPA: ABVX): Investor Relations Program

LifeSci has worked extensively with Abivax since 2015 to optimize and improve company positioning to actively increase visibility amongst investors and strategics internationally. With iterative...

Read More
Femasys (NASDAQ:FEMY): High-Net-Worth Event

BACKGROUND Femasys Inc. has been a LifeSci client since July 2021. As part of a strategy to raise the Company’s visibility amongst global investors, LifeSci...

Read More

Questions for our team?